Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on ...

Abivax SA ADR (NASDAQ:ABVX) shares rose 2.6% in premarket trading on Thursday after the clinical-stage biotechnology company announced that 22 scientific abstracts have been accepted for presentation ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Investing.com -- Abivax SA ADR (NASDAQ:ABVX) stock rose 2.6% in premarket trading Thursday after the clinical-stage biotechnology company announced the acceptance of 22 scientific abstracts for ...

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 ...

Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

Abivax is preparing a regulatory submission in the U.S. in the second half of 2026, provided an ongoing maintenance trial ...

This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...

Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...